| Ticker | Status | Jurisdiction | Filing Date | CP Start | CP End | CP Loss | Deadline |
|---|
| Ticker | Case Name | Status | CP Start | CP End | Deadline | Settlement Amt |
|---|
| Ticker | Name | Date | Analyst Firm | Up/Down | Target ($) | Rating Change | Rating Current |
|---|
Psychedelics-focused mental health care company Numinus Wellness Inc. (TSXV:NUMI) (OTCQX:NUMIF) announced its fiscal fourth quarter and full-year results Thursday for the periods ended August 31, 2021, with quarterly revenue of CA$500,000 ($394,153) up by 81% from the same period year ago. The Vancouver, British Columbia-based company noted that revenue was primarily impacted by the acquisition of Mindspace.
"During the fourth quarter we were focused on building the team, infrastructure, technologies and protocols that will allow us to scale our business over the next several years," Payton Nyquvest, founder and CEO stated. "We welcomed several new key executives, began our laboratory expansion, and filed a patent for a proprietary rapid production process for psilocybe."
Price Action
Numinus shares closed Thursday market session 1.35% higher at 41 cents per share.
Photo: Courtesy of David Clode on Unsplash